Health.Global (539787) Aug 2026 Filing Analysis

Q1 FY27 revenue grew 13.4% year over year, below the 15%+ growth guidance. Volume growth of 11% exceeded its approximate 10% component, but ARPP rose only 2%, below the approximate 5% component. The presentation does not explicitly revise or withdraw the ongoing guidance. (1 missed across 1 tracked commitment)

Management will pursue value-accretive M&A opportunities aligned with its values and aimed at expanding in new or existing markets. (+1 more commitment)

Management expects North Bangalore to achieve monthly breakeven during FY27 and reach 60%–65% optimal utilization in its third to fourth year of operation. — target: Monthly breakeven in FY27; 60%–65% utilization in the third to fourth year of operation

Improve case mix through talent-building and focused marketing across payor types, without setting a quantified mix or market-share target. (+1 more commitment)

Management plans to continue investing in clinical technology and specialist capabilities, including TomoTherapy, MR-LINAC, surgical robots, and oncology talent, to improve case mix and support margin expansion.

The December 2025 presentation cited a network of 400+ oncologists. The later baseline reports 450+ revenue-generating oncologists and 88% retention in FY26. The reported oncologist network grew by at least 12.5%, with retention information newly quantified in the later period. (1 expanding)

South accounted for 39% of HCG revenue in FY25, versus 40% in Q1 FY27. The share rose by 1 percentage point (about 2.6% relative), while the later baseline reports year-on-year revenue growth of about 16%. The share comparison is small; the latest reported revenue trajectory is positive. (5 expanding across 4 engines)

HCG reported 38 LINACs, 19 PET-CT scanners and 8 surgical robots in December 2025. The later baseline reports 38 LINACs, 20 PET-CT scanners and 11 robotic systems. LINAC count was stable, PET-CT capacity increased about 5.3%, and robotics expanded about 37.5%, strengthening the technology offering. (4 expanding, 1 stable across 1 engine)

HCG added 121 operational beds in Q1 FY27 and plans a further 815 beds through FY30: 65 in FY27, 520 across FY28–FY29, and 230 in FY30. Nearly 60% of planned expansion is at existing hospitals, with three new-hospital projects also in the pipeline. The transcript refers to Slide 12 of the investor presentation for additional detail, but does not state the total bed base or expansion capex. (+1 more signal)

HCG is adding higher-complexity cancer treatments and technology—including CAR-T cell therapy, bone marrow transplant programs, precision diagnostics and genomics, advanced radiation treatment, and robotic surgery—to attract and treat more complex cases. The company gives no launch dates or expected revenue contribution for these programs.

Latest East-region performance is growing, but at a slower rate than the prior extracted rates: Q3 FY26 revenue growth is 12% versus 22% previously, and patient-volume growth is 16% versus 25% previously. Revenue increased from Rs. 641 million to Rs. 721 million in the quarter, while revenue per patient fell 3% year on year. The prior period is unspecified, so the comparison indicates slower reported growth but is not a fully dated quarter-by-quarter series. (2 decelerating, 3 new trend across 5 signals, 1 leading indicator)

HCG reports FY2025 international revenue of Rs. 43 crore, while also saying international business is currently about 3% of total sales. The Kenya centre is described as continuing to perform well, but this document provides no earlier comparable revenue or growth rates. The contribution is therefore a newly reported baseline, not evidence of acceleration or deceleration. (1 new trend, 1 accelerating, 2 decelerating across 4 signals)

The supplied prior signal describes a first-quarter launch with Rs. 67 million revenue, over 550 registrations and more than 300 admissions, but does not identify the quarter. This presentation gives the planned capacity and expected opening timing, not operating results. There is therefore no new comparable operating data here to judge the ramp-up trajectory. (1 discontinued, 2 new trend across 3 signals)

The Dec 2025 plan was to add about 1,000 beds, including roughly 700 through brownfield expansion and 200–400 through greenfield projects, over the coming years. The Aug 2026 baseline identifies a later North Bangalore project of 520 beds planned for FY28–FY29 and says utilization may take until the third or fourth operating year to reach 60%–65%. This later, more specific outlook confirms a prolonged ramp-up risk; no project delay or cost overrun is quantified. (5 intensifying)

The Dec 2025 transcript reported West-cluster revenue of INR 990 crore in FY25, with 17% revenue CAGR since FY20, 10% volume growth, and 6% ARPP growth; it did not state that scheme business was being reduced. The Aug 2026 baseline later reports a deliberate reduction in low-margin government treatments, institutional business down more than 4% year on year, and West-cluster revenue growth of 9%. This later evidence indicates a more visible near-term revenue trade-off. (4 intensifying, 1 emerging)

The Dec 2025 transcript reported FY20–FY25 average realization per patient (ARPP) improvement of 2% in the South cluster, compared with 6% in the West and 9% in the East. Management expected 4%–5% realization improvement annually and planned to add more complex clinical programs and improve the patient mix. The Aug 2026 baseline later reports West-cluster ARPP growth of 2% in Q1 FY27 and identifies fewer high-value therapies and a higher medical-oncology share as constraints. The later evidence shows that realization growth remains modest and mix-sensitive. (4 intensifying, 1 stable)

Expansion plans were concrete in this earlier period: North Bangalore, with more than 120 planned beds, was expected to open by the end of Q4 FY26; Whitefield and other centre expansions were also planned. Management said growth would be phased and maintained guidance of 15%+ rather than the higher growth implied by the capacity pipeline, citing competitive intensity and pricing sensitivity. The Aug 2026 baseline describes a longer utilization ramp and a larger later bed plan, but the document does not provide a comparable utilization or delay figure; the change in risk level cannot be established. (1 insufficient_data, 3 intensifying)

At the earlier FY26 point, HCG reported that the Hebbal facility had opened in May 2026 with capacity of up to 132 beds and was preparing for phased scale-up; around 200 additional beds were also planned over the following 24 months. The later baseline says utilization of 60%–65% is expected only in years three to four and notes 520 beds planned for FY28–FY29. The longer stated utilization runway and larger future build-out leave material delivery and ramp-up risk; no project-level cost or overrun data is provided. (3 intensifying, 2 easing)